SCHEMBL17773780

SCHEMBL17773780

COC(=O)Cc1ccccc1OCc1cc(-c2cccc(CNC(=O)OC(C)(C)C)c2)cc(C(NC(=O)c2ccccc2)C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 11/20 0.43
TPSB2 P20231 9/20 0.43
F11 P03951 9/20 0.43
HDAC1 Q13547 2/20 0.39
PLG P00747 2/20 0.38
PLAU P00749 2/20 0.38
KLKB1 P03952 2/20 0.38
F7 P08709 2/20 0.38
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
F2 P00734 1/20 0.36
F9 P00740 1/20 0.36
F10 P00742 1/20 0.36
PLAT P00750 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC18A2 Q05940 1/20 0.36
PDE4D Q08499 1/20 0.36
KCNH2 Q12809 1/20 0.36
MRGPRX4 Q96LA9 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17773759 0.91 CFD (0.45) CFDTPSB2F11HDAC1PLG
SCHEMBL17773796 0.90 CFD (0.46) CFDTPSB2F11HDAC1PLG
SCHEMBL16396528 0.87 CFD (0.47) CFDTPSB2F11HDAC1PLG
SCHEMBL16396818 0.86 CFD (0.41) CFDTPSB2F11HDAC1PLG
SCHEMBL17773751 0.86 CFD (0.44) CFDTPSB2F11HDAC1PLG
SCHEMBL16410359 0.84 CFD (0.43) CFDTPSB2F11HDAC1PLG
SCHEMBL16410286 0.83 CFD (0.51) CFDTPSB2F11HDAC1PLG
SCHEMBL16410413 0.82 CFD (0.57) CFDTPSB2F11PLGPLAU
SCHEMBL16397061 0.81 CFD (0.48) CFDTPSB2F11PLGPLAU
SCHEMBL16397839 0.81 CFD (0.53) CFDTPSB2F11HDAC1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885TPSB2 248/4885F11 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.